Literature DB >> 11889189

A switch in dehydrogenase to reductase activity of 11 beta-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells.

Iwona J Bujalska1, Elizabeth A Walker, Martin Hewison, Paul M Stewart.   

Abstract

As exemplified in patients with Cushing's syndrome, glucocorticoids play an important role in regulating adipose tissue distribution and function, but circulating cortisol concentrations are normal in most patients with obesity. However, human omental adipose stromal cells (ASCs) can generate glucocorticoid locally through the expression of the enzyme 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) type 1 (11 beta-HSD1), which, in intact cells, has been considered to be an oxoreductase, converting inactive cortisone (E) to cortisol (F). Locally produced F can induce ASC differentiation, but the relationship between 11 beta-HSD1 expression and adipocyte differentiation is unknown. Primary cultures of paired omental (om) and sc ASC and adipocytes were prepared from 17 patients undergoing elective abdominal surgery and cultured for up to 14 d. Expression and activity of 11 beta-HSD isozymes were analyzed together with early (lipoprotein lipase) and terminal (glycerol 3 phosphate dehydrogenase) markers of adipocyte differentiation. On d 1 of culture, 11 beta-HSD1 activity in intact om ASCs exceeded oxoreductase activity in every patient (78.9 +/- 24.9 vs. 15.8 +/- 3.7 [mean +/- SE] pmol/mg per hour, P < 0.001), and in sc ASCs, relative activities were similar (40.6 +/- 12.2 vs. 36.9 +/- 8.8). Conversely, in freshly isolated om adipocytes, reductase activity exceeded dehydrogenase activity (23.6 +/- 1.5 vs. 6.2 +/- 0.8 pmol/mg per hour, P < 0.01). Following 14 d of culture in serum-free conditions with addition of 10 nM insulin (Ctr) or insulin with 100 nM F (+F), lipoprotein lipase/18S RNA levels increased in both the Ctr- and +F-treated ASCs, but glycerol 3 phosphate dehydrogenase increased only in the +F cultures. In both cases, however, 11 beta-HSD1 oxoreductase activity exceeded dehydrogenase activity (Ctr: 53.3 +/- 9.0 vs. 32.4 +/- 10.5, P < 0.05; +F: 65.6 +/- 15.6 vs. 37.1 +/- 11.5 pmol/mg per hour, P < 0.05), despite no significant changes in 11 beta-HSD1 mRNA levels. In sc ASCs, dehydrogenase activity was similar to reductase activity in both Ctr- and +F-treated cells. Type 2 11 beta-HSD expression was undetectable in each case. These data show that in intact, undifferentiated om ASCs, 11 beta-HSD1 acts primarily as a dehydrogenase, but in mature adipocytes oxoreductase activity predominates. Because glucocorticoids inhibit cell proliferation, we postulate that 11 beta-HSD1 activity in uncommitted ASCs may facilitate proliferation rather than differentiation. Once early differentiation is initiated, a "switch" to 11 beta-HSD1 oxoreductase activity generates F, thus promoting adipogenesis. Site-specific regulation of the set-point of 11 beta-HSD1 activity may be an important mechanism underpinning visceral obesity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11889189     DOI: 10.1210/jcem.87.3.8301

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

Review 1.  Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.

Authors:  Deborah J Wake; Brian R Walker
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 2.  Is "Cushing's disease of the omentum" an affliction of mouse and men?

Authors:  B R Walker
Journal:  Diabetologia       Date:  2004-04-17       Impact factor: 10.122

3.  G6PT-H6PDH-11βHSD1 triad in the liver and its implication in the pathomechanism of the metabolic syndrome.

Authors:  Ibolya Czegle; Miklós Csala; József Mandl; Angelo Benedetti; István Karádi; Gábor Bánhegyi
Journal:  World J Hepatol       Date:  2012-04-27

Review 4.  The biological actions of dehydroepiandrosterone involves multiple receptors.

Authors:  Stephanie J Webb; Thomas E Geoghegan; Russell A Prough; Kristy K Michael Miller
Journal:  Drug Metab Rev       Date:  2006       Impact factor: 4.518

Review 5.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

Review 6.  Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?

Authors:  Elise P Gomez-Sanchez
Journal:  J Cardiovasc Pharmacol       Date:  2016-01       Impact factor: 3.105

7.  Intrafollicular cortisol levels inversely correlate with cumulus cell lipid content as a possible energy source during oocyte meiotic resumption in women undergoing ovarian stimulation for in vitro fertilization.

Authors:  Ariel A Simerman; David L Hill; Tristan R Grogan; David Elashoff; Nigel J Clarke; Ellen H Goldstein; Alexa N Manrriquez; Gregorio D Chazenbalk; Daniel A Dumesic
Journal:  Fertil Steril       Date:  2014-10-24       Impact factor: 7.329

Review 8.  Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system.

Authors:  Andrzej T Slominski; Michal A Zmijewski; Cezary Skobowiat; Blazej Zbytek; Radomir M Slominski; Jeffery D Steketee
Journal:  Adv Anat Embryol Cell Biol       Date:  2012       Impact factor: 1.231

Review 9.  11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes.

Authors:  T M Stulnig; W Waldhäusl
Journal:  Diabetologia       Date:  2003-12-03       Impact factor: 10.122

Review 10.  Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis.

Authors:  Elise P Gomez-Sanchez
Journal:  Steroids       Date:  2014-12       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.